| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14,725 |
13,809 |
$766K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
12,355 |
11,653 |
$427K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
724 |
698 |
$75K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
943 |
909 |
$60K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
457 |
424 |
$29K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
323 |
308 |
$26K |
| 96127 |
|
5,387 |
5,202 |
$17K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
914 |
857 |
$13K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
100 |
97 |
$7K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
154 |
112 |
$6K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
135 |
125 |
$4K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
40 |
40 |
$3K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
19 |
19 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
531 |
509 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
57 |
53 |
$1K |
| 99406 |
|
107 |
101 |
$916.30 |
| 86328 |
|
12 |
12 |
$394.14 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
30 |
25 |
$359.62 |
| 36416 |
|
12 |
12 |
$30.39 |